Der Patentauslauf stellt eines der wichtigsten Ereignisse im Lebenszyklus pharmazeutischer
Produkte dar. Nach dem Ende des Patentschutzes drängen nicht selten Dutzende …

The combination of higher costs of drug development and an increasing share of generics
has lead pharmaceutical firms to focus on alternative strategies to make profits. An important …

The pharmaceutical industry is characterized by high R&D costs and increasing competition.
New pharmaceutical products are often provided patent protection to help companies …

Zusammenfassung Die Europäische Kommission veröffentlichte 2009 die Ergebnisse einer
Untersuchung des Arzneimittelsektors. Ausgangspunkt der Untersuchung war die Annahme …

Over the past few decades, increasingly sophisticated patent strategies have been
employed by many companies in the research-based pharmaceutical industry to protect …

REPORT is a need for better understanding of the relationship between patents and
exclusivity, along with the balance between protecting innovation and promoting access to …

Patents are effective tools for promoting innovation in the pharmaceutical sector. Originator
companies should be able to recoup their R&D investments during the term of the basic …

Highlights•Two key elements of drug LCM are market exclusivity and patent protection.•The
USA and Japan have different patent term extension systems.•There are substantial …

Abstract" Evergreening" is a pejorative term used to refer to the practice of extending the
length of patent protection beyond the statutory term of 20 years, most often used in the …

The expiration of patent protection and the subsequent sharp decline in sales have become
a crucial topic for many pharmaceutical companies in recent years. The effort invested in …